mozavaptan has been researched along with tolvaptan in 12 studies
| Studies (mozavaptan) | Trials (mozavaptan) | Recent Studies (post-2010) (mozavaptan) | Studies (tolvaptan) | Trials (tolvaptan) | Recent Studies (post-2010) (tolvaptan) |
|---|---|---|---|---|---|
| 165 | 8 | 24 | 967 | 172 | 786 |
| Protein | Taxonomy | mozavaptan (IC50) | tolvaptan (IC50) |
|---|---|---|---|
| Bile salt export pump | Homo sapiens (human) | 9.99 | |
| Vasopressin V2 receptor | Homo sapiens (human) | 0.1486 | |
| Vasopressin V1a receptor | Homo sapiens (human) | 0.351 |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (16.67) | 18.2507 |
| 2000's | 5 (41.67) | 29.6817 |
| 2010's | 4 (33.33) | 24.3611 |
| 2020's | 1 (8.33) | 2.80 |
| Authors | Studies |
|---|---|
| Aoyama, M; Hirano, T; Itoh, S; Kondo, K; Kotosai, K; Mori, T; Nakamura, S; Ogawa, H; Onogawa, T; Tominaga, M; Tsujimae, K; Tsujimoto, G; Yamada, Y; Yamamura, Y; Yamashita, H; Yamashita, T | 1 |
| Kitano, K; Kondo, K; Miyamoto, H; Mori, T; Nakamura, S; Nakaya, K; Ogawa, H; Onogawa, T; Tanaka, M; Tominaga, M; Yamamura, Y; Yamashita, H | 1 |
| Hirano, T; Itai, A; Kan, K; Kondo, K; Kurimura, M; Mori, T; Nakamura, S; Ogawa, H; Shinohara, T; Tanada, Y; Tominaga, M; Yamamura, Y; Yamashita, H | 1 |
| Balding, LC; Burrell, LM; Johnston, CI; Naitoh, M; Risvanis, J | 1 |
| Gattone, V; Harris, PC; Torres, VE; Wang, X | 1 |
| Gross, P; Herbrig, K; Palm, C; Pistrosch, F | 1 |
| Torres, VE | 1 |
| Villabona, C | 1 |
| Akioka, Y; Fujita, T; Hashimoto, M; Hisano, M; Igarashi, T; Iida, A; Iiri, T; Makita, N; Manaka, K; Miura, K; Sekine, T; Takahashi, K; Takubo, N; Ueda, N | 1 |
| Dabrowska, MD; Krysiak, R; Okopień, B | 1 |
| Iwao, H; Izumi, Y; Miura, K | 1 |
| Hammond, S; Meng, X; Mosedale, M; Naisbitt, DJ | 1 |
6 review(s) available for mozavaptan and tolvaptan
| Article | Year |
|---|---|
Vasopressin receptor antagonism--a therapeutic option in heart failure and hypertension.
Topics: Antidiuretic Hormone Receptor Antagonists; Benzazepines; Heart Failure; Humans; Hypertension; Morpholines; Receptors, Vasopressin; Spiro Compounds; Tolvaptan | 2000 |
Vasopressin antagonists as aquaretic agents for the treatment of hyponatremia.
Topics: Antidiuretic Hormone Receptor Antagonists; Azepines; Benzamides; Benzazepines; Humans; Hyponatremia; Inappropriate ADH Syndrome; Morpholines; Pyrroles; Randomized Controlled Trials as Topic; Spiro Compounds; Tolvaptan; Vasopressins | 2006 |
Role of vasopressin antagonists.
Topics: Adolescent; Adult; Animals; Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Benzazepines; Body Fluids; Cell Proliferation; Drug Evaluation, Preclinical; Hormone Antagonists; Humans; Kidney; Male; Polycystic Kidney, Autosomal Dominant; Receptors, Vasopressin; Tolvaptan; Treatment Outcome | 2008 |
[Vasopressin receptor antagonists: the vaptans].
Topics: Adult; Antidiuretic Hormone Receptor Antagonists; Aquaporin 2; Benzamides; Benzazepines; Calcium Signaling; Clinical Trials as Topic; Cyclic AMP; Double-Blind Method; Drug Therapy, Combination; Heart Failure; Humans; Hyponatremia; Inappropriate ADH Syndrome; Kidney Tubules, Collecting; Liver Cirrhosis; Morpholines; Multicenter Studies as Topic; Neoplasms; Pituitary Gland, Anterior; Pyrroles; Randomized Controlled Trials as Topic; Receptors, Vasopressin; Second Messenger Systems; Spiro Compounds; Tolvaptan; Vasopressins | 2010 |
[Hyponatremic hypervolemia in heart failure--the hot spot for vasopressin receptor antagonists?].
Topics: Antidiuretic Hormone Receptor Antagonists; Benzamides; Benzazepines; Diuretics; Heart Failure; Humans; Hyponatremia; Hypovolemia; Morpholines; Pyrroles; Spiro Compounds; Tolvaptan | 2012 |
Therapeutic potential of vasopressin-receptor antagonists in heart failure.
Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Benzamides; Benzazepines; Body Water; Clinical Trials as Topic; Disease Models, Animal; Heart Failure; Homeostasis; Humans; Hyponatremia; Morpholines; Pyrroles; Receptors, Vasopressin; Spiro Compounds; Tolvaptan; Ventricular Remodeling | 2014 |
6 other study(ies) available for mozavaptan and tolvaptan
| Article | Year |
|---|---|
OPC-41061, a highly potent human vasopressin V2-receptor antagonist: pharmacological profile and aquaretic effect by single and multiple oral dosing in rats.
Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Benzazepines; Blood Urea Nitrogen; Creatinine; Diuretics; Dose-Response Relationship, Drug; HeLa Cells; Humans; Male; Osmolar Concentration; Rats; Rats, Sprague-Dawley; Receptors, Vasopressin; Sodium; Tolvaptan; Transfection | 1998 |
7-Chloro-5-hydroxy-1-[2-methyl-4-(2-methylbenzoyl-amino)benzoyl ]-2,3,4,5-tetrahydro-1H-1-benzazepine (OPC-41061): a potent, orally active nonpeptide arginine vasopressin V2 receptor antagonist.
Topics: Animals; Antidiuretic Hormone Receptor Antagonists; Arginine Vasopressin; Benzazepines; Diuretics; Magnetic Resonance Spectroscopy; Male; Molecular Structure; Radioligand Assay; Rats; Rats, Sprague-Dawley; Receptors, Vasopressin; Tolvaptan | 1999 |
Novel design of nonpeptide AVP V(2) receptor agonists: structural requirements for an agonist having 1-(4-aminobenzoyl)-2,3,4, 5-tetrahydro-1H-1-benzazepine as a template.
Topics: Administration, Oral; Animals; Arginine Vasopressin; Benzazepines; Cyclic AMP; Diuresis; Drug Design; Female; HeLa Cells; Humans; Models, Molecular; Molecular Conformation; Radioligand Assay; Rats; Receptors, Vasopressin; Structure-Activity Relationship | 2000 |
Effectiveness of vasopressin V2 receptor antagonists OPC-31260 and OPC-41061 on polycystic kidney disease development in the PCK rat.
Topics: Adenine; Animals; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Cyclic AMP; Disease Models, Animal; Extracellular Signal-Regulated MAP Kinases; Female; Guanosine Triphosphate; Introns; Kidney; Male; Phosphorylation; Polycystic Kidney Diseases; Polycystic Kidney, Autosomal Recessive; Proto-Oncogene Proteins B-raf; ras Proteins; Rats; Rats, Sprague-Dawley; Receptors, Cell Surface; Thymine; Tolvaptan | 2005 |
V2 vasopressin receptor (V2R) mutations in partial nephrogenic diabetes insipidus highlight protean agonism of V2R antagonists.
Topics: Amino Acid Substitution; Animals; Antidiuretic Hormone Receptor Antagonists; Benzazepines; Cell Membrane; Child; Child, Preschool; Chlorocebus aethiops; COS Cells; Diabetes Insipidus, Nephrogenic; Humans; Male; Mutation, Missense; Neurophysins; Protein Precursors; Receptors, Vasopressin; Tolvaptan; Vasopressins | 2012 |
Activation of tolvaptan-responsive T-cell clones with the structurally-related mozavaptan.
Topics: Antidiuretic Hormone Receptor Antagonists; Clone Cells; Humans; Polycystic Kidney, Autosomal Dominant; T-Lymphocytes; Tolvaptan | 2023 |